Kornimate/medical-research-clean huggingface dataset:
effects of aquatic exercise on post-exercise hypotension

Conditions: Hypertension; Aging; Obesity

Summary: this is a randomized controlled trial. the present study involves an acute and chronic intervention, which is a water-based exercise (one session: to acute intervention; 12-weeks of aquatic exercise program: to chronic intervention). the sample will be composed by elderly enrolled in university extension program titled "hidroginastica na terceira idade" (hydrogymnastics in aging). it will be evaluated the effects of water-based exercise on hemodynamics, self-reported sleep quality, depressive symptoms, quality of life, body composition, level of physical activity and functional capacity. the investigators hypothesized that an acute water-based exercise under different intensities promotes hemodynamics changes in elderly. in addition, the investigators hypothesized that 12-weeks of aquatic exercise may lead improvements in self-reported sleep quality, depressive symptoms, quality of life, body composition, level of physical activity and functional capacity in elderly.


Eligibility criteria:
inclusion criteria: * elderly (60 years and over) * able to practice physical exercise in water * able to answer all questionnaires * non-smoker exclusion criteria: * morbid obese * those who not complete all data collection procedures

Keywords: hemodynamics aquatic exercise elderly
effect of mulligan'mobilization with movement on pain, disability and range of motion in patients with knee osteoarthritis

Conditions: Physical Fittness

Summary: we tested the effect of adding the mobilization with movement to the traditional physical therapy program on pain, rom and functional disability in patients with knee oa. study hypothesis: there will be no significant difference between traditional physical therapy program and the mobilization with movement plus the traditional physical therapy program on pain, rom and functional disability in patients with knee oa


Eligibility criteria:
inclusion criteria: * patients with unilateral osteoarthritis knee age ranges from 30-60 years old grade 1 or 2 on kallegren and lawerance scale. body mass index not more than 36 exclusion criteria: * history of major knee injury or surgery, tumors, osteoporosis, patients undertaking analgesics, patients with uncontrolled hypertension, bleeding, dermatological problems, psychiatric disorders, hearing problems, cognitive problems and pacemaker.

Keywords: mobilization with movement,knee osteoarthritis,
intron a for the treatment of hypertrophic scar

Conditions: Burn; Hypertrophic Scar

Summary: this study assesses the intervention with antifibrotic agents, specifically interferon (ifn) to reduce the magnitude and duration of hypertrophic scar. burn patients with hypertrophic scar are randomly assigned to either an intervention ifn group or a placebo control group by subcutaneous injection three times a week. patients are assessed using cutometer, mexameter, standardized photography, urinalysis, blood work, tissue biopsies and the vancouver burn scar assessment (vbsa) which rates selected hts based on color, vascularity, height, pliability, itchiness and pain sensitivity. once on treatment patients are assessed monthly for the six month treatment period.

burn patients being followed and treated in the outpatient burn clinic with large areas of hts are approached to participate in the study. patients who agree to participate and who have signed an informed consent are entered into the trial. pre-treatment evaluation and monthly examinations include: * standardized photographs of scar * scar volume * vancouver burn scar assessment (vbsa) * blood work (tgf-beta, histamine) * urine collection (histamine) * 6mm punch biopsy of hts and adjacent normal skin (every two months) patients are randomized to received with placebo or intron a 1x106 iu a day for 7 days, then 3x106 iu 3 sc, three times a week for 23 weeks.

Eligibility criteria:
inclusion criteria: * burns \> 5% tbsa * informed consent * no prior exposure to interferon or other cytokines exclusion criteria: * history of cardiac or cns disorder or disease * autoimmune disease * immunodeficiency * abnormal renal or hepatic function * pregnancy * serious intercurrent illness * active infection * malnutrition * active drug or alcohol abuse

Keywords: burn hypertrophic scar fibroproliferative disorder
performance and safety of a second generation antimicrobial graft in abdominal position

Conditions: Abdominal Aorta Aneurysm

Summary: safety and performance of an anti-microbial vascular graft in the treatment of aneurysmal and occlusive disease of the abdominal aorta.

the purpose of this multi center, single arm study is to demonstrate the safety and performance of the second generation anti-microbial (intergard synergy) vascular graft in the treatment of aneurismal and occlusive diseases of the abdominal aorta. the primary endpoint is the assessment of primary and secondary graft patency. the secondary endpoints were the assessment of adverse events and the assessment of triclosan and silver contents in the serum over the time.

Eligibility criteria:
inclusion criteria: patient aged 18-85 years patient presenting with an aorto-iliac occlusion (obstruction of flow) or stenosis, or aorto-iliac aneurysm and eligible for a revascularization with a bifurcated graft exclusion criteria: patient treated as an emergency patient included in another investigation patient pregnant or lactating or woman of childbearing potential patient with a known allergy to the material device used (collagen, triclosan, silver) patient with previous aorto-iliac bypass or replacement
ozone gel application in controlled type 2 diabetic patients with periodontitis

Conditions: Periodontal Diseases

Summary: the adjunctive topical subgingival application ozone gel creates a great improvements in the clinical, bacteriological and immunological parameters over the gold standard of periodontal pocket treatment alone.

the aim of this study is to compare the effect of using ozone gel as a locally delivered adjunct to scaling and root planning versus scaling and root planning alone on the clinical parameters in stageiii grade b in periodontitis patients with controlled diabetic patients.

Eligibility criteria:
inclusion criteria: 1. patient with controlled diabetic type ii. (hga1c \<7) (mori et al., 2021) 2. adult patients above 18 years old. 3. patients with stage iii and grade b periodontitis. 4. patients accept 3-months follow-up period (cooperative patients). 5. patients provide an informed consent exclusion criteria: * 1. presence of prosthetic crowns. 2. extensive restorations. 3. periodontal therapy within the last 12 months. 4. having surgical therapy or undergoing orthodontic treatment. 5. ongoing drug therapy that might have an impact on the clinical signs and symptoms of periodontitis. 6. the use of antibiotics or anti-inflammatory drugs 1 month prior to the procedure and till the end of 3 months of follow-up. 7. smokers. 8. pregnant females. 9. any known allergies
reveal for respiration detection

Conditions: Unexplained Syncope; Suspected Arrhythmia

Summary: this study will evaluate the correlation between the respiratory rate derived from the reveal insertable cardiac monitor (icm) electrocardiogram (ecg) with the respiratory rate obtained from an external respiratory band in patients previously implanted with a reveal for unexplained syncope or suspected arrhythmia.


Eligibility criteria:
inclusion criteria: * subject is implanted with a reveal icm or reveal xt icm for unexplained syncope or suspected arrhythmia * subject (or the legal representative) is willing to sign informed consent form * subject is 18 years or older or as specified minimal age per local law/regulation exclusion criteria: * significant respiratory diseases such as copd or pulmonary hypertension. * patients with frequent arrhythmias, including pvc's. * patients with known heart failure. * body conditions that would complicate accurate measurement of respiratory rate with the respiration device. * patients which are not able to take the postures as necessary for the study protocol and which cannot walk continuously for a period of 6 minutes. * pregnant or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth control. * subject is enrolled in one or more concurrent studies that would confound the results of this study
efficacy and safety of qva149 in patients with chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: this study will evaluate the safety and efficacy of qva149 in patients with moderate to severe copd.


Eligibility criteria:
inclusion criteria: 1. male or female adults aged ≥40 years, who have signed an informed consent form prior to initiation of any study-related procedure. 2. patients with moderate to severe stable chronic obstructive pulmonary disease (copd) according to the global initiative for obstructive lung disease (gold) guidelines 2006. 3. patients who have smoking history of at least 10 pack years. 4. patients with a post-bronchodilator forced expiratory volume in 1 second (fev1) ≥30% and \< 80% of the predicted normal and post-bronchodilator fev1/forced vital capacity (fvc) \<0.70. exclusion criteria: 1. pregnant or nursing women, or women of child-bearing potential, regardless of whether or not sexually active if they are not using acceptable methods of contraception. 2. patients requiring long term oxygen therapy (\> 15 hours a day) on a daily basis for chronic hypoxemia, or who have been hospitalized or visited an emergency department for a copd exacerbation or as result of their airways disease in the 6 weeks prior to screening. 3. patients who have had a respiratory tract infection within 6 weeks prior to screening. 4. patients with concomitant pulmonary disease, pulmonary tuberculosis (unless confirmed by chest x-ray to be no longer active) or clinically significant bronchiectasis. 5. patients with any history of asthma indicated by (but not limited to) a blood eosinophil count \> 400/mm3. 6. patients who, in the judgment of the investigator or the responsible novartis personnel, have a clinically relevant laboratory abnormality or a clinically significant condition. 7. patients with uncontrolled type i and type ii diabetes. 8. history of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years. 9. patients who are contraindicated for or who have shown an untoward reaction to inhaled anticholinergic agents. 10. patients with a history of long qt syndrome or whose qtc interval (fridericia method) measured at screening is prolonged (\>450 ms for males or \>470 ms for females). 11. patients with a history of untoward reactions to sympathomimetic amines, inhaled medication or any component thereof, or any of the study drugs or drugs with similar chemical structures. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: qva, indacaterol, glycopyrrolate, concept1, copd, cross over study, safety and efficacy, trough fev1
rituximab in combination with outpatient therapy for cd20+ lymphoma

Conditions: Non-Hodgkin's Lymphoma (CD20+)

Summary: this is a phase ii pilot study evaluating the safety of a risk-adjusted outpatient-based approach to lymphoma salvage therapy with vgf (vinorelbine, gemcitabine and pegfilgrastim) and/or f-giv (gemcitabine, ifosfamide, vinorelbine and pegfilgrastim) in combination with rituximab (r-vgf/r-f-giv).

recent epidemiologic surveys have demonstrated a dramatic increase in the incidence of non-hodgkin's lymphoma (nhl). nhl is now one of the most rapidly increasing malignancies in the industrial world. the purpose of this project is to evaluate the efficacy and safety of an outpatient treatment for relapsed or treatment resistant (refractory) cd20+ lymphoma. two combinations of chemotherapy drugs will be tested depending on the patients prior therapy and response - rituximab, vinorelbine and gemcitabine (r-vgf) or rituximab, vinorelbine, gemcitabine and ifosfamide (r-fgiv). previous experience, including a recently completed study using combinations of vinorelbine, gemcitabine and ifosfamide has demonstrated that such an outpatient approach is safe and of similar efficacy to presently available alternative inpatient chemotherapy approaches. this study is expanding on the findings from the previous study by adding rituximab. rituximab is being increasingly and successfully used in the therapy of cd20+ nhl. it is a specific protein (antibody) that is directed against the surface protein (cd20 antigen) found on cd20+ lymphoma cells and can therefore lead to the destruction of these cells. rituximab also has a highly favourable toxicity profile enabling outpatient treatment. all of these factors provide a strong rationale for the combination of rituximab and the novel outpatient-based salvage approaches vgf and f-giv that we have recently evaluated. this pilot study of 12 patients will test the feasibility of this combination approach in patients with relapsed/refractory cd20+ nhl.

Eligibility criteria:
inclusion criteria: * age \>18 years * relapsed or primary refractory cd20+ nhl * ecog 0 - 2 * written informed consent exclusion criteria: * intention to proceed with any form of transplant therapy following fewer than 2 cycles of protocol salvage therapy. * bilirubin \> 50µmol/litre unless secondary to lymphoma * creatinine \> 2 x upper limit of normal unless secondary to lymphoma * absolute neutrophil count \<0.5 x 109/litre and / or platelets \< 50 x 109/litre unless secondary to lymphoma * relapse within 6 months of a prior transplant procedure (autologous or allogeneic). * known sensitivity to e coli derived preparations

Keywords: lymphoma cd20+
diabetes prevention strategies in women with gestational diabetes mellitus (gdm)

Conditions: Gestational Diabetes; Obesity

Summary: the main goal of this study is to examine the comparative effectiveness of diabetes prevention strategies in women with gestational diabetes mellitus (gdm) on the control of the following conditions: obesity, hyperglycemia, hypertension and depression. this randomized lifestyle intervention study will be conducted at kaiser permanente northern california. women in the intervention will receive a letter on gestational weight gain during pregnancy and in the postpartum period, a curriculum of individualized lifestyle counseling via telephone, augmented with e-mail and an interactive web site. patients randomized to the usual care arm will receive the standard-care telephone calls from the perinatal center during pregnancy and the center's printed educational materials postpartum. outcomes will be assessed through the electronic medical record and patient surveys conducted during pregnancy and at 6-weeks, 6- months and 1-year postpartum.


Eligibility criteria:
inclusion criteria: all women, 18 years of age or older, receiving medical care at kaiser permanente northern california with a pregnancy complicated by gestational diabetes between march 2011 and may 2012 that have a telephone or cellular phone will be eligible. exclusion criteria: women with overt diabetes not recognized prior to pregnancy (any women with fasting plasma glucose \> 126 mg/dl, or any plasma glucose level over 200 mg/dl on more than 1 occasion during pregnancy) will be excluded from the analyses but will be eligible for the lifestyle intervention.
a study of lepodisiran (ly3819469) in participants with normal, mild, moderate, or severe liver function

Conditions: Liver Dysfunction; Healthy

Summary: the main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (sc) injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. the study will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants. the study will last up to approximately 9 weeks, excluding screening.


Eligibility criteria:
inclusion criteria: * have a body weight of 55 kilogram (kg) or more and body mass index within the range 19.0 to 42.0 kilogram per square meter (kg/m²) * additional inclusion criteria for participants without hepatic impairment in group 1: * healthy participants with clinically normal hepatic function * for participants with mild to severe hepatic impairment in groups 2 through 4: * participants with hepatic impairment classified as child-pugh score a, b, or c (mild, moderate, or severe impairment). diagnosis of chronic hepatic impairment of greater than 6 months, per physician diagnosis and standard-of-care practice exclusion criteria: * have significant history of, or current, cardiovascular (cv), respiratory, hepatic (hepatic applies to group 1 only), renal, gastrointestinal, endocrine, hematological, or neurological disorders * have severe atopy or a history of clinically significant multiple or severe drug allergies * have known allergies to lepodisiran, related compounds, or any components of the formulation * have a history of, or current, psychiatric disorders * have had any malignancy within the past 5 years * have estimated glomerular filtration rate (egfr) less than 60 milliliters per minute per 1.73 m² (ml/min/1.73 m²) using the chronic kidney disease epidemiology collaboration (ckd-epi) equation * have participated, within the last 1 month, in a clinical study involving an investigational product
selective extended dissection in different types of pancreatic head cancer: a retrospective cohort study.

Conditions: Carcinoma, Pancreatic Ductal

Summary: pancreatic ductal adenocarcinoma (pdac) is a highly malignant tumor with relatively poor survival. surgery is the first choice for the treatment of patients with early pancreatic cancer. however, the surgical approach and the extent of resection for patients with pancreatic cancer are controversial at present. the investigators optimized the procedure of standard pancreaticoduodenectomy to selective extended dissection (sed), which is based on the extra-pancreatic nerve plexus (plx) potentially invaded by tumor. the investigators retrospectively analyzed the clinicopathological data of patients with pancreatic adenocarcinoma who underwent radical surgery in our center from 2011 to 2020. patients who underwent standard dissection (sd) were matched 2:1 to those who underwent sed using propensity score matching (psm). the log-rank test and cox regression model were used to analyze survival data. in addition, statistical analyses were performed for the perioperative complications, postoperative pathology and recurrence pattern.


Eligibility criteria:
inclusion criteria: - 1) patients diagnosed as resectable pancreatic cancer were pathologically diagnosed as pdac after surgery. 2) patients received radical surgery (r0) and had complete photos or videos of the operation. exclusion criteria: - 1) the operation records as well as related photo or video data could not reflect the surgical approach and the extent of resection. 2) patients with incomplete clinical, pathological, imaging and follow-up information.
telemonitoring and teleintervention of heart failure and decrease of non-fatal events.

Conditions: Heart Failure

Summary: the primary objective of the study is to determine the effect of automated daily selfreported symptom and weight, blood pressure and heart rate monitoring and clinical follow-up videoconference comigrate with clinical follow-up face in specialized hospital unit in reducing heart failure non-fatal events.

the insuﬁcie 'ncia cardı´aca optimitzacio ´ remota (icor; heart failure remote optimization) trial was a singlecentre, randomized, open-label study designed to evaluate the eﬃcacy of the addition of telemedicine (telemonitorization and teleintervention using videoconference) to an existing specialized, multidisciplinary, nurse-based, hospitalprimary care integrated hf programme for high-risk patients with chf. the organizational characteristics of the programme and the impact in health outcomes resulting from its implementation have been previously published.2 in this study we aimed to compare the strategy of providing nurse-based structured follow-up to high-risk chf patients through planned contacts between health care providers and patients and/or caregivers in the basis of face-to-face on-site encounters (usual care in our hf programme) or provide the planned care using telemedicine with the combination of remote daily monitoring of signs and symptoms of hf (telemonitoring) and delivery of structured nursebased follow-up health care using videoconference (teleintervention). the main hypothesis of this study was that adding telemedicine to an existing hf programme would be associated with a reduction in the number of non-fatal hf events in high-risk patients with chf. as a secondary hypothesis we assumed that adding telemedicine would translate into a reduction in health care resource utilization and subsequently in health care costs.

Eligibility criteria:
inclusion criteria: * patients discharged from a heart failure hospitalization within 30 days of enrollment into the study. exclusion criteria: * less than 18 years * long-term nursing home residence, irreversible medical conditions, folstein mini-mental state exam score less than 20. * no access to 3g line, currently scheduled for cardiac transplant, left ventricular assist device or valvular surgery,coronary intervention within 90 days of randomisation.

Keywords: telemonitoring heart failure
retrospective analysis of the geriatric patients underwent unilateral inguinal herniorrhaphy

Conditions: Inguinal Hernia

Summary: the aim of this study is to compare the geriatric patients with the non-geriatrics undergoing outpatient unilateral herniorrhapy in terms of local anesthesia, sedation, recovery and early morbidity.

a retrospective data analysis will be conducted and the patient records will be evaluated for patient characteristics local anesthesia, sedation, recovery and early morbidity.

Eligibility criteria:
inclusion criteria: patients with a unilateral inguinal hernia undergoing herniorrhaphy exclusion criteria: none
audit of the response time of the anaesthetic and surgical techniques for crash caesarean section

Conditions: Pregnancy; Anaesthesia

Summary: a decision-to-delivery interval of 30 minutes for category-1 caesarean section deliveries is the standard of practice recommended by clinical guidelines.

our institution established a protocol for category-1 ('crash') cs to expedite deliveries. this retrospective audit evaluated all women who underwent category-1 cs in kk women's and children's hospital from 2010 to 2013.

Eligibility criteria:
inclusion criteria: * category one caesarean section at kk women's and children's hospital, singapore between 2010 to 2013. exclusion criteria: * no specific exclusion criteria, retrospective audit

Keywords: caesarean section emergency anaesthesia